Benzinga | Nov 9, 2021 11:31AM EST

ALX Oncology Announces Updated Data From Ongoing Clinical Trial Of Evorpacept Showing Emerging Clinical Benefit In Survival-Based Endpoints In Patients With Advanced Solid Tumors

-- ORR of 72.2%, mDOR of 14.8 months, 12-month OS rate of 79%, and mOS of 17.1 months in Patients with >2L HER2 Positive Gastric/Gastroesophageal Junction Cancer --

-- 12-month OS rate of 87.5% and mOS not reached in Patients with 1L Head and Neck Cancer --

-- 12-month OS rate of 80% and mOS of 24.5 months in Patients with Checkpoint Na?ve >2L Head and Neck Cancer --

__

-- ALX Oncology to Host Conference Call on November 9 at 8:00 a.m. EST --